$GILD (Gilead Sciences Inc.)

$GILD {{ '2016-02-25T17:27:44+0000' | timeago}} • Announcement

Biopharmaceutical company $GILD said that its Marketing Authorization Application (MAA) for tenofovir alafenamide (TAF) 25mg has been fully validated and is under assessment by the European Medicines Agency (EMA). This drug is an investigational, once-daily treatment for adults with chronic hepatitis B virus infection, an inflammation of the liver.

$GILD {{ '2017-07-27T19:17:21+0000' | timeago}} • Webcast

$GILD stated that for Genvoya, it is starting to see performance trends similar to that of the US in other countries like Germany. The company is seeing good uptake in Spain and Italy. France has also done extraordinarily well in just four months to become the leading naïve and switch product.

$GILD {{ '2017-07-27T19:04:57+0000' | timeago}} • Webcast

For HCV, $GILD’s total revenues in the US were $1.9Bil in 2Q17, down 17% YoY and up 13% sequentially. The QoQ increase was primarily due to a change in inventory and the timing of patient starts. In Europe, total HCV revenue was $591MM, down 24% YoY and up 21% from 1Q17.

$GILD {{ '2017-07-27T19:00:11+0000' | timeago}} • Webcast

$GILD is seeing strong uptake of its TAF-based regimens in the US and Europe. In the US, total HIV and HBV revenues were $2.6Bil for 2Q17, up 19% YoY and up 10% sequentially. In Europe, total HIV and HBV revenues were $732MM, down 3% YoY and up 5% sequentially. The YoY decrease was driven by negative foreign exchange.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$GILD {{ '2017-07-24T13:41:56+0000' | timeago}} • Announcement

$GILD announced results from two Phase 3 studies evaluating the efficacy and safety of a fixed-dose combination of bictegravir (BIC) and emtricitabine/tenofovir alafenamide (FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. This regimen has been well tolerated with low rates of discontinuations due to adverse events.

$GILD {{ '2017-07-18T20:14:00+0000' | timeago}} • Announcement

$GILD said the US FDA has approved Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults previously treated with or without an NS5A inhibitor-containing regimen. The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies.

$GILD {{ '2017-07-13T13:10:29+0000' | timeago}} • Announcement

$GILD said its Marketing Authorization Application for an investigational, once-daily single tablet regimen containing bictegravir and emtricitabine/tenofovir alafenamide, formulations for treatment of HIV-1 infection in adults, has been fully validated. Currently, they are under evaluation by the European Medicines Agency.

$GILD {{ '2017-06-23T12:05:41+0000' | timeago}} • Announcement

$GILD said the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency(EMA), has adopted a positive opinion on its Marketing Authorization Application (MAA) for Vosevi for the treatment of chronic hepatitis C virus (HCV)-infected patients.

$GILD {{ '2017-06-12T15:03:28+0000' | timeago}} • Announcement

$GILD has submitted a New Drug Application to the FDA for an investigational, once-daily single tablet regimen for the treatment of HIV-1 infection in adults.

$GILD {{ '2017-05-30T14:13:41+0000' | timeago}} • Announcement

$GILD announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC)  and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection met their primary objectives of non-inferiority.

$GILD {{ '2017-05-05T19:17:07+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphics: Q1 2017 highlights

$GILD {{ '2017-05-02T21:57:30+0000' | timeago}} • Webcast

$GILD stated that the news about futility analysis is a rumor. The company clarified that it does not have an interim analysis planned in Phase III study. The study will be carried out for 48 weeks, $GILD said.

$GILD {{ '2017-05-02T21:45:49+0000' | timeago}} • Webcast

$GILD stated that about 55% of HIV sales is from public and about 45% is from the private in U.S. Of that 55%, 20% or so is from AIDS Drug Assistance Program (ADAP).

$GILD {{ '2017-05-02T21:24:29+0000' | timeago}} • Announcement

$GILD BoD has declared a cash dividend of $0.52 per share of common stock for 2Q17. The dividend is payable on June 29, 2017, to stockholders of record as on June 16, 2017.

$GILD {{ '2017-05-02T20:29:54+0000' | timeago}} • Announcement

$GILD's total product sales for 1Q17 were $6.4Bil compared to $7.7Bil for the same period in 2016. Geographically, sales were $4.5Bil in the US, $1.3Bil in Europe and $661MM in other locations.This compares to prior-year period's sales of $4.4Bil in the US, $1.6Bil in Europe and $1.7Bil in other locations.

$GILD {{ '2017-05-02T20:24:45+0000' | timeago}} • Announcement

$GILD reiterated its FY17 guidance provided on February 7, 2017. Product sales are predicted in the range of $22.5-24.5Bil, while Product Gross Margin is expected between 86% and 88%.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
VICL (Vical Incorporated)
Monday, May 15 2017 - 4:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
RGEN (Repligen Corporation)
Thursday, May 4 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
INSM (Insmed Incorporated)
Wednesday, May 3 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
MNTA (Momenta Pharmaceuticals Inc.)
Tuesday, May 2 2017 - 2:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm

AlphaGraphics you may like